A coronavirus disease (COVID-19) vaccine from Novavax proved 96.4 percent effective in the final efficacy analysis from its Phase 3 clinical trial conducted in the United Kingdom.
Results of the vaccine’s Phase 3 trial also showed an 86.3 percent efficacy against B.1.1.7 variant first reported in the UK.
Meanwhile, the vaccine was found to be 55.4 percent effective against the B.1.351 variant that was first traced to South Africa.
“Because of the encouraging results, numerous studies have been expanded to include adolescents (12-17 years old), pregnant women, as well as on its potential use as booster in combination with other COVID-19 vaccines, and for seasonal revaccination,” local distributor Fabreco Life Sciences Inc. said.
It added that Novavax has expanded its manufacturing capacity, with several partners including the Serum Institute of India (SII) to meet the global demand.
Novavax and SII eye to commence delivery of the Covovax vaccines in the third quarter of 2021.
Fabreco Life Sciences. Inc. said it will proceed with the emergency use authorization (EUA) application with the Food and Drug Administration.
EUA from the United States, United Kingdom, European Medicines Agency, Canada, Australia, New Zealand, and the Republic of Korea are expected to be released soon.
The Philippines has signed a supply agreement securing 30 million doses of the Novavax COVID-19 vaccine in March.